Compare Amazon.com Inc (AMZN) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amazon.com Inc vs Mesoblast Limited — how do they compare? Amazon.com Inc trades at $244.66 (market cap $2.64T), while Mesoblast Limited trades at $16.01 (market cap $2.00B). The key difference: Amazon.com Inc is far larger — about 1320× Mesoblast Limited's market cap. Which is the better fit depends on your goals.
| AMZN | MESO | |
|---|---|---|
Market Cap | $2.64T | $2.00B |
Volume | 3,931,282 | — |
Sector | Consumer Cyclical | Technology |
52-Week High | $274.95 | $20.96 |
52-Week Low | $198.79 | $10.96 |
Enterprise Value | $2.71T | $2.00B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amazon (AMZN) trades at $245.34, down 0.69% on the day, with strong technical momentum showing a bullish moving average signal. The company demonstrates robust fundamentals with revenue growth from $638B in 2024 to $716.9B in 2025 and net income surging to $77.67B. Recent CEO communications highlight Amazon's AI chip business reaching $20+ billion run-rate and strong visibility into future cash flows from massive capital investments.
Amazon presents a compelling investment case with 88% analyst buy ratings and a $320.75 consensus price target representing 31% upside. Key opportunities include AWS growth and AI leadership, while risks involve intense retail competition and the sustainability of massive capital expenditures. The stock's current valuation at 29.35 P/E appears reasonable given growth trajectory and profitability improvements.
MESO trades at $15.44, up 4.11% today, with a bullish technical signal from moving averages but overbought RSI near 89. The company reported a net loss of $102.14 million in 2025 despite an 80.52% gross margin, while recent news highlights Ryoncil revenue growth and FDA progress for its heart failure treatment, signaling a transition to commercial operations.
The outlook is cautiously optimistic, driven by product commercialization and pipeline advancements, but high cash burn and negative margins pose significant risks. Analyst consensus leans buy (45% of ratings), yet the stock's elevated P/S ratio of 30.52 demands careful valuation assessment amid ongoing losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amazon.com Inc
Amazon.com, Inc. is an online retailer that offers a wide range of products. The Company products include books, music, computers, electronics and numerous other products. Amazon offers personalized shopping services, Web-based credit card payment, and direct shipping to customers. Amazon also operates a cloud platform offering services globally.
Read more on AMZN →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
